KLK4 and acquired angioedema: When patients with AAE-C1-INH were treated for attacks on-demand with the bradykinin B2 receptor antagonist (Icatibant) or the kallikrein inhibitor (Ecallantide), an improved attack resolution was demonstrated [16, 17].